Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation (Q39020147)

From Wikidata

Jump to navigation Jump to search

scientific article published on 27 February 2014

Language	Label	Description	Also known as
English	Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation	scientific article published on 27 February 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation (English)

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

prostate cancer

1 reference

based on heuristic

inferred from title

cancer metastasis

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Lei Gu

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Pooja Talati

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Paraskevi Vogiatzi

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Ana L Romero-Weaver

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Junaid Abdulghani

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Zhiyong Liao

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Benjamin Leiby

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

David T Hoang

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Kalle Alanen

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Michael Zinda

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Dennis Huszar

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Marja T Nevalainen

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

27 February 2014

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

Molecular Cancer Therapeutics

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1246-1258

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Targeting JAK2 in the therapy of myeloproliferative neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

The changing therapeutic landscape of castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Stat3 promotes metastatic progression of prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

The metastatic cascade in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Regulation of cancer cell motility through actin reorganization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Interleukin-6 regulation of prostate cancer cell growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Actin and microtubules in cell motility: which one is in control?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Interleukin-6 is an autocrine growth factor in human prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

9 September 2017

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

14 September 2017

N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

14 September 2017

Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

14 September 2017

C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

14 September 2017

Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

14 September 2017

STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells .

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

25 September 2017

STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

25 September 2017

Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

25 September 2017

Interleukin-6: a candidate mediator of human prostate cancer morbidity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

25 September 2017

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

17 June 2018

Signal transducers and activators of transcription mediate fibroblast growth factor-induced vascular endothelial morphogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

17 June 2018

Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

17 June 2018

Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

17 June 2018

Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

17 June 2018

Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

21 August 2018

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

21 August 2018

Blockade of interleukin-6 receptor suppresses reactive astrogliosis and ameliorates functional recovery in experimental spinal cord injury

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

21 August 2018

Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4013199

21 August 2018

Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24577942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum interleukin 6 as a prognostic factor in patients with prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24577942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokine variations in patients with hormone treated prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24577942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24577942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade

1 reference

https://pubmed.ncbi.nlm.nih.gov/24577942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/24577942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24577942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence

1 reference

https://pubmed.ncbi.nlm.nih.gov/24577942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1535-7163.MCT-13-0605

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577942%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39020147&oldid=1940838335"